Press Releases Year None202320222021 November 13, 2023 NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter 2023 Financial Highlights October 23, 2023 NewAmsterdam Pharma Announces Appointment of Ian Somaiya as Chief Financial Officer September 21, 2023 NewAmsterdam Pharma Announces Initial Data from Phase 2a Clinical Trial Evaluating Obicetrapib in Patients with Early Alzheimer’s Disease Who Carry an ApoE4 Mutation September 20, 2023 NewAmsterdam Pharma to Present at 2023 Cantor Fitzgerald Global Healthcare Conference August 14, 2023 NewAmsterdam Pharma Announces Appointment of William “BJ” Jones, formerly of Biohaven Pharmaceuticals, as Chief Commercial Officer August 7, 2023 NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter 2023 Financial Highlights July 25, 2023 NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia and/or Established Atherosclerotic Cardiovascular Disease June 9, 2023 NewAmsterdam Pharma Announces Closing of Upsized Secondary Offering of Ordinary Shares June 6, 2023 NewAmsterdam Pharma Announces Pricing of Upsized Secondary Offering of Ordinary Shares June 6, 2023 NewAmsterdam Pharma Announces Commencement of Secondary Offering of Ordinary Shares Pagination Current page 1 Page 2 Page 3 Next page next › Last page last » Displaying 1 - 10 of 22
November 13, 2023 NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter 2023 Financial Highlights
September 21, 2023 NewAmsterdam Pharma Announces Initial Data from Phase 2a Clinical Trial Evaluating Obicetrapib in Patients with Early Alzheimer’s Disease Who Carry an ApoE4 Mutation
September 20, 2023 NewAmsterdam Pharma to Present at 2023 Cantor Fitzgerald Global Healthcare Conference
August 14, 2023 NewAmsterdam Pharma Announces Appointment of William “BJ” Jones, formerly of Biohaven Pharmaceuticals, as Chief Commercial Officer
August 7, 2023 NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter 2023 Financial Highlights
July 25, 2023 NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia and/or Established Atherosclerotic Cardiovascular Disease
